Sicart Associates’s Kyntra Bio KYNB Stock Holding History

Sicart Associates’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-443	Closed	-$475K	–	110
2019 Q4	$475K	Sell	443 -600	-58%	-$613K	0.16%	72
2019 Q3	$964K	Hold	1,043	–	–	0.32%	43
2019 Q2	$1.18M	Hold	1,043	–	–	0.48%	40
2019 Q1	$1.42M	Hold	1,043	–	–	0.6%	35
2018 Q4	$1.21M	Hold	1,043	–	–	0.58%	35
2018 Q3	$1.58M	Hold	1,043	–	–	0.76%	32
2018 Q2	$1.63M	Sell	1,043 -200	-16%	-$261K	0.86%	28
2018 Q1	$1.44M	Hold	1,243	–	–	0.86%	31
2017 Q4	$1.47M	Hold	1,243	–	–	0.78%	39
2017 Q3	$1.67M	Hold	1,243	–	–	1.2%	25
2017 Q2	$1M	Hold	1,243	–	–	0.73%	34
2017 Q1	$766K	Buy	+1,243	New	+$757K	0.55%	43

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Sicart Associates's KYNB Position: Q1 2020 in Review

Sicart Associates sold out of Kyntra Bio (KYNB) in Q1 2020, closing a stake of 443 shares — an estimated $475K sold.

Sicart Associates first reported a position in KYNB in Q1 2017 and held it in 12 quarters. The position peaked at $1.67M in Q3 2017. 187 funds tracked by Wall St. Rank hold KYNB as of Q1 2020.

Sicart Associates reported no remaining Kyntra Bio position as of Q1 2020 after selling out during the quarter.
Sicart Associates sold 443 Kyntra Bio shares in Q1 2020, an estimated $475K.
Sicart Associates first reported a position in Kyntra Bio in Q1 2017 and held it in 12 quarters.
Sicart Associates's Kyntra Bio position peaked at $1.67M in Q3 2017.
187 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2020.

Based on Sicart Associates's 13F filing for Q1 2020, filed 22 Apr 2020.